Delta Sleep-Inducing Peptide

Potential Benefits of Delta Sleep-Inducing Peptide

• Improves Sleep Quality [1-15]
• Reduces Chronic Pain [16-18]
• Fights Stress [19-26]
• Boosts Brain Power [27-34]
• Treats Depression [16, 35-39]
• Lowers the Risk of Heart Disease [40-43]
• Lowers Blood Pressure [44-45]
• Prevents Cancer and Reduces the Side Effects of Chemotherapy [46-47]
• Treats Symptoms of Diabetes [48-50]
• Provides Support for Alcohol and Drug Withdrawal [51-54]

What is Delta Sleep-Inducing Peptide?

Delta sleep-inducing peptide, also known as DSIP, was first detected in rabbits’ brains back in 1977. As its name suggests, DSIP is used to promote sleep and help people with different types of sleeping problems. Numerous studies have proven its beneficial effects on sleep quality without any adverse effects. As a potent antioxidant, DSIP may help support the central nervous and endocrine systems by reducing the levels of damaging free radicals.

How Delta Sleep-Inducing Peptide Works?

Delta sleep-inducing peptide works by targeting multiple sites in the brain including the brainstem to induce sleep. It interacts with the hormones serotonin and melatonin which are involved in the induction of sleep and regulation of sleep patterns.

Chemical Structure of Delta Sleep-Inducing Peptide

Research on Delta Sleep-Inducing Peptide

Improves Sleep Quality

A number of studies support the beneficial effects of DSIP on sleep quality and quantity:

1. A study showed that DSIP can stimulate sleep in disturbed human sleep patterns. [1]
2. In patients with insomnia, DSIP injection resulted in longer sleep duration with reduced interruptions. [2-6]
3. In cats, a single injection of DSIP effectively shortened sleep latency and significantly increased the total sleep duration. [7]
4. Studies showed that DSIP was effective in inducing delta sleep (deep stage of sleep) in rabbits, rats, mice, cats, and humans. [8-11]
5. A study showed that high-dose administration of DSIP was associated with improvements in symptoms of insomnia. [12]
6. In healthy individuals, DSIP was effective in inducing sleep without any side effects. [13]
7. Studies described DSIP as a sleep-promoting peptide rather than a sedative. [14-15]

Reduces Chronic Pain

Evidence suggests that DSIP has pain-relieving properties:

1. In patients with chronic, pronounced pain episodes, the intravenous administration of DSIP lowered the pain levels of the subjects. [16]
2. In mice and rats that had undergone the tail-pinch and hot-plate tests, pretreatment with DSIP produced pain-relieving effects. [17]
3. The administration of DSIP reduced pain levels in patients with headaches and other pain syndromes. [18]

Fights Stress

DSIP has also been shown to help fight stress:

1. In animal models of stress, DSIP administration reduced behaviors associated with stress. [19-20]
2. In rats, DSIP injections significantly increased acute emotional stress resistance. [21]
3. In rats treated with chlorpromazine-morphine-pentobarbital, DSIP administration significantly reduced the levels of the stress hormone cortisol. [22-23]
4. In rats, higher levels of DSIP were associated with more resistance to emotional stress. [24-26]

Boosts Brain Power

DSIP is not only vital for sleep but also for brain health:

1. In rats, DSIP injections significantly increased their resistance against acute emotional stress. [27]
2. A study showed that the stress-protective effects of DSIP can be attributed to its antioxidant properties. [28]
3. In rats with cerebral ischemia (low blood supply in the brain), DSIP administration resulted in increased blood supply and higher survival rates. [29]
4. In adult male rats, DSIP administration greatly reduced the occurrence, duration, and severity of seizures, suggesting that it is a suitable antiepileptic drug. [30-31]
5. In animals with cerebral ischemia, DSIP reduced the severity and lethality of the condition. [32]
6. In rats, the improved sleep quality from DSIP injection further resulted in the restoration of spatial memory. [33]
7. In a rat model of stroke, the administration of DSIP resulted in significant reductions in the severity of postural abnormalities. [34]

Treats Depression

There’s also compelling evidence supporting the antidepressant properties of DSIP:

1. In patients with chronic, pronounced pain episodes, the intravenous administration of DSIP resulted in a significant reduction in depressive states. [16]
2. In patients diagnosed with depression, low blood levels of DSIP were found. [35-38]
3. In rats with anxious depression, DSIP produced anti-anxiety effects as evidenced by improved scores in the elevated plus-maze and tail suspension test. [39]

Lowers the Risk of Heart Disease

Studies suggest that DSIP also has cardioprotective effects:

1. In rabbits, DSIP administration corrected abnormal heart rhythm. [40]
2. In rats and rabbits, DSIP restored normal heart rhythm during the occurrence of emotional stress. [41]
3. In animal models, DSIP injection reduced abnormally fast heart rate. [42]
4. In male rabbits, DSIP improved blood flow via direct actions on heart function. [43]

Lowers Blood Pressure

There are also studies supporting the anti-hypertensive effects of DSIP:

1. In spontaneously hypertensive rats (SHR), subcutaneous injection of DSIP significantly reduced the blood pressure of the subjects. [44]
2. Administration of DSIP in hypertensive rats at 200 μg kg daily for 10 days lowered blood pressure. [45]

Prevents Cancer and Reduces the Side Effects of Chemotherapy

Evidence also suggests that DSIP possesses anti-cancer properties:

1. In hypertensive rats, DSIP treatment was associated with a lower risk of tumor growth. [46]
2. A study showed that DSIP can enhance the effects of chemotherapeutic drugs while reducing its unwanted side effects. [47]

Treats Symptoms of Diabetes

DSIP has also been shown to have beneficial effects on symptoms of diabetes:

1. In elderly diabetic patients, a daily dose of DSIP improved quality of life and reduced mood depression and emotional lability. [48]
2. In diabetic patients with eye complications, a daily dose of 0.0003 g of DSIP intranasally for two months improved visual function. [49-50]

Provides Support for Alcohol and Drug Withdrawal

A good deal of evidence suggests that DSIP can help reduce the symptoms associated with alcohol and drug withdrawal:

1. A study reported that DSIP can be safely and effectively used in opioid detoxification. [51]
2. In alcoholics and opiate addicts, the intravenous injection of DSIP (25 nmol/kg) resulted in the suspension of the somatic symptoms and signs as well as anxiety. [52-54]

Associated Side Effects of Delta Sleep-Inducing Peptide

DSIP side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on DSIP. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of DSIP. Despite this, it was listed as a side effect associated with DSIP even though these associated side effects are very uncommon.

Side effects associated with DSIP may include the following:

• Headache
• Hypotension (low blood pressure)
• Vagal reactions (dizziness, ringing ears, and sweating)
• Vomiting

References

1. Lyle H. Miller, Barry A. Turnbull, Abba J. Kastin, David H. Coy, Sleep-Wave Activity of a Delta Sleep-Inducing Peptide Analog Correlates with its Penetrance of the Blood-Brain Barrier, Sleep, Volume 9, Issue 1, March 1986, Pages 80–84, https://doi.org/10.1093/sleep/9.1.80.
2. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(9):913-7. doi: 10.1007/BF01971753. PMID: 7028502.
3. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-7. doi: 10.1159/000118919. PMID: 1299794.
4. Graf, M. V., & Kastin, A. J. (1986). Delta-sleep-inducing peptide (DSIP): an update. Peptides, 7(6), 1165–1187. https://doi.org/10.1016/0196-9781(86)90148-8.
5. Schneider-Helmert D. (1984). DSIP in insomnia. European neurology, 23(5), 358–363. https://doi.org/10.1159/000115714.
6. Schneider-Helmert, D., Hermann, E., & Schoenenberger, G. A. (1987). Korrektur einer Insomnie mit Phasenverschiebung durch DSIP [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia]. Deutsche medizinische Wochenschrift (1946), 112(23), 922–925. https://doi.org/10.1055/s-2008-1068167.
7. Susić V, Masirević G, Totić S. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Res. 1987 Jun 30;414(2):262-70. doi: 10.1016/0006-8993(87)90006-0. PMID: 3620931.
8. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984 Spring;8(1):83-93. doi: 10.1016/0149-7634(84)90022-8. PMID: 6145137.
9. Schoenenberger G. A. (1984). Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). European neurology, 23(5), 321–345. https://doi.org/10.1159/000115711.
10. Constantinidis, J., Bouras, C., Guntern, R., Taban, C. H., & Tissot, R. (1983). Delta sleep-inducing peptide in the rat brain: an immunohistological microscopic study. Neuropsychobiology, 10(2-3), 94–100. https://doi.org/10.1159/000117992.
11. Scherschlicht, R., Aeppli, L., Polc, P., & Haefely, W. (1984). Some pharmacological effects of delta-sleep-inducing peptide (DSIP). European neurology, 23(5), 346–352. https://doi.org/10.1159/000115712.
12. Schneider-Helmert D. DSIP in insomnia. Eur Neurol. 1984;23(5):358-63. doi: 10.1159/000115714. PMID: 6391925.
13. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. PMID: 6895513.
14. Graf, M. V., & Kastin, A. J. (1984). Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and biobehavioral reviews, 8(1), 83–93. https://doi.org/10.1016/0149-7634(84)90022-8.
15. Available from https://www.cambridge.org/core/journals/european-journal-of-anaesthesiology/article/delta-sleepinducing-peptide/04EA29FACB57F0D24E6FCD4B7E54AA00.
16. Larbig, W., Gerber, W. D., Kluck, M., & Schoenenberger, G. A. (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. European neurology, 23(5), 372–385. https://doi.org/10.1159/000115716.
17. Nakamura, A., Nakashima, M., Sugao, T., Kanemoto, H., Fukumura, Y., & Shiomi, H. (1988). Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). European journal of pharmacology, 155(3), 247–253. https://doi.org/10.1016/0014-2999(88)90510-9.
18. Available from https://journals.sagepub.com/doi/abs/10.1177/03331024870070S614.
19. Graf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. J Neurochem. 1987 Apr;48(4):1252-7. doi: 10.1111/j.1471-4159.1987.tb05654.x. PMID: 3029331.
20. Miller LH, Turnbull BA, Kastin AJ, Coy DH. Sleep-wave activity of a delta sleep-inducing peptide analog correlates with its penetrance of the blood-brain barrier. Sleep. 1986;9(1):80-4. doi: 10.1093/sleep/9.1.80. PMID: 3754348.
21. Salieva RM, Ianovskiĭ K, Ratsak R, Trofimova IaI, Oehme P, Sudakov KV, Iumatov EA. Peptid, vyzyvaiushchiĭ del’ta-son, kak faktor, povyshaiushchiĭ soderzhanie veshchestva P v gipotalamuse i ustoĭchivost’ krys k émotsional’nomu stressu [The delta sleep-inducing peptide as a factor enhancing the content of substance P in the hypothalamus and the resistance of rats to emotional stress]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1991 May-Jun;41(3):558-63. Russian. PMID: 1718095.
22. Sudakov KV, Ivanov VT, Koplik EV, Vedjaev DF, Michaleva II, Sargsjan AS. Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals’ resistance to acute emotional stress. Pavlov J Biol Sci. 1983 Jan-Mar;18(1):1-5. doi: 10.1007/BF03004904. PMID: 6687936.
23. Graf MV, Kastin AJ, Coy DH, Fischman AJ. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Neuroendocrinology. 1985 Oct;41(4):353-6. doi: 10.1159/000124200. PMID: 2995861.
24. Bondarenko TI, Milyutina NP, Shustanova TA, Mikhaleva II. The effects of delta sleep-inducing peptide on the intensity of lipid peroxidation and xanthine oxidase activity in rat tissues during cold stress. Neurosci Behav Physiol. 2001 Jan-Feb;31(1):83-6. doi: 10.1023/a:1026686516768. PMID: 11265821.
25. Salieva RM, Koplik EV, Kamenov ZA, Poletaev AB. Vliianie beta-éndorfina i peptida, vyzyvaiushchego del’ta-son, na ustoĭchivost’ k émotional’nomu stressu [Effects of beta endorphin and delta-sleep inducing peptide on resistance to emotional stress]. Biull Eksp Biol Med. 1989 Oct;108(10):464-6. Russian. PMID: 2532045.
26. Salieva RM, Koplik EV, Kamenov ZA, Poletaev AB. Peptid, vyzyvaiushchiĭ del’ta-son, v krovi i gipotalamuse u krys s razlichnoĭ ustoĭchivost’iu k émotsional’nomu stressu [Delta sleep-inducing peptide in the blood and hypothalamus of rats with various resistance to emotional stress]. Biull Eksp Biol Med. 1988 Sep;106(9):264-6. Russian. PMID: 3167172.
27. Sudakov, K.V., Ivanov, V.T., Koplik, E.V. et al. Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals’ resistance to acute emotional stress. Pav. J. Biol. Sci. 18, 1–5 (1983). https://doi.org/10.1007/BF03004904.
28. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003 Feb;24(2):307-11. doi: 10.1016/s0196-9781(03)00040-8. PMID: 12668217.
29. Koplik EV, Umryukhin PE, Konorova IL, Terekhina OL, Mikhaleva II, Gannushkina IV, Sudakov KV. Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection. Neurosci Behav Physiol. 2008 Nov;38(9):953-7. doi: 10.1007/s11055-008-9076-4. PMID: 18975104.
30. Stanojlovic O, Zivanovic D, Susic V. Delta-peptid spavanja i njegov uticaj na elektroencefalogram i spektralnu gustinu snage kod pacova s metafitskom epilepsijom [The delta-sleep inducing peptide and its effect on the electroencephalogram and power spectrum density in rats with metaphit-induced epilepsy]. Srp Arh Celok Lek. 2001 May-Jun;129(5-6):114-8. Serbian. PMID: 11797457.
31. Shandra AA, Godlevskii LS, Brusentsov AI, Petrashevich VP, Vast’yanov RS, Nikel B, Mikhaleva II. Delta-sleep-inducing peptide and its analogs and the serotoninergic system in the development of anticonvulsive influences. Neurosci Behav Physiol. 1998 Sep-Oct;28(5):521-6. doi: 10.1007/BF02463012. PMID: 9809291.
32. Shandra AA, Godlevskii LS, Brusentsov AI, Vast’yanov RS, Karlyuga VA, Dzygal AF, Nikel B. Effects of delta-sleep-inducing peptide in cerebral ischemia in rats. Neurosci Behav Physiol. 1998 Jul-Aug;28(4):443-6. doi: 10.1007/BF02464804. PMID: 9762721.
33. Roy K, Chauhan G, Kumari P, Wadhwa M, Alam S, Ray K, Panjwani U, Kishore K. Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude. Life Sci. 2018 Sep 15;209:282-290. doi: 10.1016/j.lfs.2018.08.026. Epub 2018 Aug 11. PMID: 30107169.
34. Shandra, A. A., Godlevskii, L. S., Brusentsov, A. I., Vast’yanov, R. S., Karlyuga, V. A., Dzygal, A. F., & Nikel, B. (1998). Effects of delta-sleep-inducing peptide in cerebral ischemia in rats. Neuroscience and behavioral physiology, 28(4), 443–446. https://doi.org/10.1007/BF02464804.
35. Lindström, L. H., Ekman, R., Walleus, H., & Widerlöv, E. (1985). Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers. Progress in neuro-psychopharmacology & biological psychiatry, 9(1), 83–90. https://doi.org/10.1016/0278-5846(85)90182-4.
36. Westrin, A., Ekman, R., & Träskman-Bendz, L. (1998). High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. Biological psychiatry, 43(10), 734–739. https://doi.org/10.1016/s0006-3223(97)00254-0.
37. Available from https://www.tandfonline.com/doi/abs/10.3109/08039488509101959.
38. Lesch, K. P., Widerlöv, E., Ekman, R., Laux, G., Schulte, H. M., Pfüller, H., & Beckmann, H. (1988). Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder. Comparison with CRH-induced corticotropin and cortisol secretion. Biological psychiatry, 24(2), 162–172. https://doi.org/10.1016/0006-3223(88)90271-5.
39. Loskutova, L. V., Shtark, M. B., & Epstein, O. I. (2003). Efficiency of ultralow doses of antibodies to S100 protein and delta sleep-inducing peptide in rats with anxious depression. Bulletin of experimental biology and medicine, 135 Suppl 7, 20–22. https://doi.org/10.1023/a:1024797722719.
40. Zviaginsteva MA. Rol’ peptida delta-sna v élektricheskoĭ stabil’nosti serdtsa [The role of delta sleep-inducing peptide in the electric stability of the heart]. Kardiologiia. 1988 Mar;28(3):89-91. Russian. PMID: 3379896.
41. Ul’ianinskiĭ LS, Ivanov VT, Mikhaleva II, Sudakov KV. Peptid del’ta-sna kak moduliator serdechnoĭ deiatel’nosti: teoreticheskie rekomendatsii dlia praktiki [Delta-sleep peptide as a modulator of cardiac activity: theoretical recommendations for practice]. Kosm Biol Aviakosm Med. 1990 May-Jun;24(3):23-8. Russian. PMID: 2197498.
42. Zviagintseva MA, Kosharskaia IL, Ul’ianinskiĭ LS. Vliianie peptida del’ta-sna na parasimpaticheskuiu reguliatsiiu serdechnogo ritma [Effect of the delta-sleep peptide on parasympathetic regulation of the cardiac rhythm]. Biull Eksp Biol Med. 1986 Apr;101(4):390-1. Russian. PMID: 3754472.
43. Pimenova TI. Gemodinamika pri deĭstvii peptida del’ta-sna [Hemodynamics as affected by delta-sleep-inducing peptide]. Patol Fiziol Eksp Ter. 1991;(6):16-8. Russian. PMID: 1818276.
44. Graf MV, Kastin AJ, Schoenenberger GA. Delta sleep-inducing peptide in spontaneously hypertensive rats. Pharmacol Biochem Behav. 1986 Jun;24(6):1797-9. doi: 10.1016/0091-3057(86)90524-1. PMID: 3755534.
45. Popovich IG, Voitenkov BO, Anisimov VN, Ivanov VT, Mikhaleva II, Zabezhinski MA, Alimova IN, Baturin DA, Zavarzina NY, Rosenfeld SV, Semenchenko AV, Yashin AI. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003 Jun;124(6):721-31. doi: 10.1016/s0047-6374(03)00082-4. PMID: 12782416.
46. Graf MV, Kastin AJ, Schoenenberger GA. Delta sleep- inducing peptide in spontaneously hypertensive rats. Pharmacol Biochem Behav 1986; 24: 1797–1799.
47. Mikhaleva II, Ivanov VT, Onoprienko LV, Prudchenko IA, Chikin LD, Yakubovskaya RI, Nemtsova ER, Bezborodova OA. [Antioxidative and detoxifying effects of analogues of delta-sleep inducing peptide (DSIP)]. Bioorg Khim. 2014 Jan-Feb;40(1):3-11. Russian. doi: 10.1134/s1068162014010087. PMID: 25898718.
48. Odin VI, Belikova TV, Pushkova ES, Barr NA. Sakharnyĭ diabet u pozhilykh: geroprotektivnye i protivodiabeticheskie svoĭstva preparata del’ta-son indutsiruiushchego peptida [Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide]. Adv Gerontol. 2004;15:101-14. Russian. PMID: 15754961.
49. Kresiun NV, Godlevskiĭ LS. [Using deltalicin for the treatment of patients with diabetic retinopathy]. Eksp Klin Farmakol. 2014;77(12):22-5. Russian. PMID: 25739189.
50. Kresyun NV. The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy. Rev Med Chir Soc Med Nat Iasi. 2014 Oct-Dec;118(4):1068-73. PMID: 25581971.
51. Backmund, M., Meyer, K., Rothenhaeusler, H. B., & Soyka, M. (1998). Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. Journal of clinical psychopharmacology, 18(3), 257–258. https://doi.org/10.1097/00004714-199806000-00016.
52. Dick, P., Grandjean, M. E., & Tissot, R. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology, 10(4), 205–208. https://doi.org/10.1159/000118012.
53. Dick, P., Costa, C., Fayolle, K., Grandjean, M. E., Khoshbeen, A., & Tissot, R. (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European neurology, 23(5), 364–371. https://doi.org/10.1159/000115715.
54. Hruz, P., Zechner, S., Heimberg, D., Hobi, V., Schönenberger, G. A., Scheffler, K., Müller-Spahn, F., & Seifritz, E. (2001). Intranasal administration of delta sleep-inducing peptide increases P300. Journal of clinical psychopharmacology, 21(6), 626–628. https://doi.org/10.1097/00004714-200112000-00021.